MK-4830

MK-4830 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for MK-4830, covering 2024-05-14 to 2025-10-07. Get the full timeline:

Most recent: Clinical Trial Update: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) [Phase 1]

See pricing